RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2023 -- Pappas Capital, a leading investor in next-generation life science and technology companies, announced today that Nick Pappas (no relation) has joined the firm as...
X-Ceptor focused on the identification of novel drug candidates that interact with orphan nuclear receptors involved in cholesterol metabolism and cardiovascular disease. Several of its programs were partnered and further developed by large pharmaceutical companies.
Exelixis acquired X-Ceptor in 2004.
X-Ceptor Therapeutics
San Diego, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.